GlaxoSmithKline Starts Two Late-Stage Trials of Melanoma Drugs

January 25, 2011 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- British drugmaker GlaxoSmithKline (GSK.L) said on Monday it was starting two global late stage trials of drugs in advanced or metastatic melanoma in patients whose tumours have a particular gene mutation.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase III

GlaxoSmithKline